Medroxyprogesterone acetate and Estradiol cypionate injection |
Lunelle |
Clinical Trial: An evaluation of safety and efficacy of Anecortave Acetate versus placebo in patients with subfoveal CNV due to exudative AMD.
This study is currently recruiting patients.
|
Purpose
To demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Macular Degeneration Maculopathy, Age-Related | Drug: anecortave acetate | Phase III |
MedlinePlus related topics: Macular Degeneration
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: An evaluation of safety and efficacy of Anecortave Acetate versus placebo in patients with subfoveal choroidal neovascularization due to exudative age-related macular degeneration.
Study start: March 2003
Eligibility
Ages Eligible for Study: 50 Years and above, Genders Eligible for Study: Both
Criteria
Location and Contact Information
South America, ; Recruiting
More Information
Record last reviewed: April 2003
Last Updated: April 16, 2003
Record first received: April 15, 2003
ClinicalTrials.gov Identifier: NCT00058994
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Lunelle (Drug Digest)
- Medroxyprogesterone acetate and Estradiol cypionate injection (Drug Digest)

Not Signed In -


